Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients

Neurology

Volumn 78, Issue 20, 2012, Pages 1601-1607

  Leite, M I ^a   Coutinho, E ^b   Lana Peixoto, M ^c   Apostolos, S ^d   Waters, P ^a   Sato, D ^d,e   Melamud, L ^f   Marta, M ^g   Graham, A ^h   Spillane, J ⁱ   Villa, A M ^f   Callegaro, D ^d   Santos, E ^b   Da Silva, A Martins ^b   Jarius, S ^j   Howard, R ⁱ   Nakashima, I ^e   Giovannoni, G ^g   Buckley, C ^a   Hilton Jones, D ^a   Vincent, A ^a   Palace, J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF PORTO   (Portugal)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f HOSPITAL RAMOS MEJÍA   (Argentina)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h Department of Neurology   (United Kingdom)

ⁱ NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^j UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; ANTIBODY; AQUAPORIN 4; AUTOANTIBODY; CHOLINERGIC RECEPTOR;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; MALE; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; THYMECTOMY; ADOLESCENT; ADULT; BLOOD; BRAIN; CHILD; CLINICAL TRIAL; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOLOGY;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIBODIES; AQUAPORIN 4; AUTOANTIBODIES; BRAIN; CHILD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMYELITIS OPTICA; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; THYMECTOMY; YOUNG ADULT;

EID: 84863580450     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31825644ff     Document Type: Article

References (34)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
2. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008;65:913-919.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
5. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
6. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
7. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009;386:623-627.
8. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
9. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133:349-361.
10. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6:383-392.
11. Hoedemaekers AC, van Breda Vriesman PJ, De Baets MH. Myasthenia gravis as a prototype autoimmune receptor disease. Immunol Res 1997;16:341-354.
12. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39:87-90.
13. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
14. Nakamura H, Usa T, Motomura M, et al. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest 2008;31:861-865.
15. Thorlacius S, Aarli JA, Riise T, Matre R, Johnsen HJ. Associated disorders in myasthenia gravis: Autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989;80:290-295.
16. Nakamura M, Nakashima I, Sato S, Miyazawa I, Fujihara K, Itoyama Y. Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands. Mult Scler 2007; 13:332-335.
17. Kay CS, Scola RH, Lorenzoni PJ, Jarius S, Arruda WO, Werneck LC. NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci 2008;275:148-150.
18. Uzawa A, Mori M, Iwai Y, et al. Association of antiaquaporin- 4 antibody-positive neuromyelitis optica with myasthenia gravis. J Neurol Sci 2009;287:105-107.
19. Kister I, Gulati S, Boz C, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006;63:851-856.
20. Gotkine M, Fellig Y, Abramsky O. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 2006;67:881-883.
21. Waters P, McKeon A, Leite M, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
22. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-712.
23. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: Diagnosis and follow-up of 100 consecutive patients. J Neurol 1997;244:112-118.
24. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in 106 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients from the United Kingdom and Japan. Brain (in press 2012).
25. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis: I: Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 1982;49:257-265.
26. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-2231.
27. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589-1595.
28. Collongues N, Marignier R, Zephir H, et al. Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology 2010;74:736-742.
29. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom- Davis J. Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Ann Neurol 1987;22:212-222.
30. Wekerle H, Ketelsen UP. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1977;1: 678-680.
31. Leite MI, Jones M, Strobel P, et al. Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007;171: 893-905.
32. Roxanis I, Micklem K, McConville J, Newsom-Davis J, Willcox N. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol 2002;125:185-197.
33. Giraud M, Taubert R, Vandiedonck C, et al. An IRF8- binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007;448: 934-937.
34. Chan KH, Kwan JS, Ho PW, et al. Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. J Neuroimmunol 2010;227:178-184.